Evidence map›Paper›PMID 20853144›Full record

ArticleMolecular biology reports2011

The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria.

Zohreh Rahimi, Vahid Felehgari, Mehrali Rahimi, Hadi Mozafari, Kheirollah Yari, Asad Vaisi-Raygani, Mansour Rezaei, Shohreh Malek-Khosravi, Habibolah Khazaie

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
3.8field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. A systematic review of the role of renin angiotensin aldosterone system genes in diabetes mellitus, diabetic retinopathy and diabetic neuropathy.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2014
    Review
  12. Association between leptin gene G-2548A polymorphism with metabolic syndrome.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013
    Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Zohreh RahimiThe Rhazes Center for Research in Family Health and Sexual Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran. zrahimi@kums.ac.ir
Vahid Felehgari
Mehrali Rahimi
Hadi Mozafari
Kheirollah Yari
Asad Vaisi-Raygani
Mansour Rezaei
Shohreh Malek-Khosravi
Habibolah Khazaie
Kermanshah University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of present study was to determine if factor V Leiden (FVL) mutation and angiotensin converting enzyme insertion/deletion (ACE I/D) polymorphism are associated with diabetic nephropathy (DN) among Kurdish population from Western Iran. This case-control study comprised 144 unrelated adult type 2 diabetic mellitus patients (T2DM) including 72 patients with microalbuminuria and 72 age and sex matched patients without nephropathy. The ACE I/D polymorphism and FVL mutation were detected by polymerase chain reaction (PCR) and PCR-RFLP, respectively. The frequency of FVL G1691A and ACE D allele in T2DM patients with microalbuminuria were 1.6 and 57%, respectively and in normoalbuminuric T2DM patients were 4.9 and 58.3%, respectively (P > 0.05). ACE genotypes affected on serum ACE activity and a better response to ACE inhibitor therapy (captopril) compared to angiotensin II receptor antagonist (losartan) was obtained with significant reduction of ACE activity in diabetic patients without nephropathy carrying DD genotype. However, the beneficial effect of losartan therapy was observed in microalbuminuric patients with II genotype compared to ID and DD genotypes.

Indexed as

AlbuminuriaAllelesAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCaptoprilDiabetes Mellitus, Type 2Diabetic NephropathiesFactor VFemaleGenetic Predisposition to DiseaseHumansIranLosartanMaleMiddle AgedMutationACE protein, humanAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsCaptoprilFactor Vfactor V LeidenLosartanPeptidyl-Dipeptidase A

Identifiers

PMID20853144
OpenAlexW2090746956

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.